Genentech is a member of the Roche Group, and Genentech commercializes Erivedge which is licensed from Curis.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Genentech is a member of the Roche Group, and Genentech commercializes Erivedge which is licensed from Curis.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
Curis (United States)
company in Lexington, United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- PR NewswireCuris to Present at Upcoming Healthcare Conferences in September LEXINGTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emav
- PR NewswireCuris to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025 LEXINGTON, Mass., July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS),